S H Ferris
Affiliation: New York University
- ADCS Prevention Instrument Project: overview and initial resultsSteven H Ferris
Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
Alzheimer Dis Assoc Disord 20:S109-23. 2006..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles...
- A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI)Steven Ferris
Alzheimer s Disease Center, Silberstein Institute, New York University School of Medicine, New York, NY 10016, USA
Int J Geriatr Psychiatry 22:448-55. 2007..To determine the safety and efficacy of memantine in treating Age-Associated Memory Impairment (AAMI)...
- General measures of cognitionSteven H Ferris
Silberstein Institute for Aging and Dementia, New York University School of Medicine, New York 10016, USA
Int Psychogeriatr 15:215-7. 2003..Validation of this new cognitive instrument will be supported by its successful use in vascular dementia clinical trials...
- Evaluation of memantine for the treatment of Alzheimer's diseaseSteven H Ferris
Alzheimer s Disease Center, Silberstein Institute for Ageing and Dementia, New York University School of Medicine, 550 First Avenue, Room MHL 310, New York, NY 10016, USA
Expert Opin Pharmacother 4:2305-13. 2003..This review provides a brief rationale for the development of memantine as a therapy for AD, as well as an overview of the pharmacology, clinical efficacy, safety and tolerability of this novel therapeutic agent...
- Differential diagnosis and clinical assessment of patients with severe Alzheimer diseaseSteven H Ferris
Silberstein Institute for Aging and Dementia, Department of Psychiatry, New York University School of Medicine, New York, New York, USA
Alzheimer Dis Assoc Disord 17:S92-5. 2003..Accurate diagnosis and continued evaluation of these aspects of AD can help guide therapy for patients in the late stage of the disease. Assessment tools specific for patients with severe AD are available for use in clinical studies...
- Clinical trials in AD: are current formats and outcome measures adequate?Steven H Ferris
New York University School of Medicine, New York 10016, USA
Alzheimer Dis Assoc Disord 16:S13-7. 2002..Research to develop more efficient assessment methods is clearly needed. Data acquisition over the Internet is potentially efficient and attractive and may become practical as Internet accessibility increases...
- Switching previous therapies for Alzheimer's disease to galantamineS H Ferris
Silberstein Aging and Dementia Research Center, Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
Clin Ther 23:A3-7. 2001..These findings suggest that discontinuation of prior AChEI treatment is not predictive of future poor response to an effective treatment...
- Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliabilityI M Monteiro
Aging and Dementia Research Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
Eur Psychiatry 16:5s-24s. 2001..69 to 0.98 for the seven symptom categories (p(s) < 0.001). For the BEHAVE-AD-FW total scores, the ICC was 0.91 (P < 0.001). These results indicate that the frequency-weighted component is a reliable addition to the BEHAVE-AD scale...
- Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imagingL S Prichep
Brain Research Laboratories, Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
Neurobiol Aging 27:471-81. 2006..These data indicate high sensitivity and specificity for baseline QEEG as a differential predictor of future cognitive state in normal, subjectively impaired elderly...
- A visual recognition memory test for the assessment of cognitive function in aging and dementiaC Flicker
Department of Psychiatry, New York University Medical Center, NY 10016
Exp Aging Res 13:127-32. 1987..Thus, although the task does not appear to be suitable for diagnostic purposes it would be useful for the assessment of treatment effects upon age-related cognitive dysfunction...
- ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versionsLon S Schneider
Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Alzheimer Dis Assoc Disord 20:S124-38. 2006..An important consideration was whether global assessments are specific and sensitive measures of change during a prevention trial...
- ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trialsDavid P Salmon
Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
Alzheimer Dis Assoc Disord 20:S139-46. 2006....
- ADCS Prevention Instrument Project: behavioral measures in primary prevention trialsJeffrey L Cummings
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
Alzheimer Dis Assoc Disord 20:S147-51. 2006..Experimental behavioral measures were included in the protocol to examine this hypothesis...
- Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's diseaseRoger Lane
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
Pharmacogenet Genomics 18:289-98. 2008..To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI)...
- Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trialPaul S Aisen
Georgetown University Medical Center, Washington, DC, USA
Curr Alzheimer Res 5:73-82. 2008..The significance of the observation that rofecoxib increased the rate of conversion from MCI to AD remains uncertain...
- ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderlyMary Sano
Mount Sinai School of Medicine, James J Peters VAMC, Bronx, NY 10468, USA
Alzheimer Dis Assoc Disord 20:S191-202. 2006..In addition, the loss that relates to the subjects' own time as they transition through cognitive impairment is not well documented...
- Mild cognitive impairment (MCI): a historical perspectiveBarry Reisberg
Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
Int Psychogeriatr 20:18-31. 2008..Nevertheless, longitudinal and other studies indicate essential compatibility between GDS stage 3 MCI and Petersen's MCI duration and outcomes...
- Supplement editorial: alzheimer diseaseSteven H Ferris
Alzheimer Dis Assoc Disord 20:S107-8. 2006
- Staging: relevance for trial design in vascular burden of the brainBarry Reisberg
William and Sylvia Silberstein Aging and Dementia Research Center, New York University School of Medicine, NY 10016, USA
Int Psychogeriatr 15:231-9. 2003..Although temporal and prognostic aspects have been studied for the Alzheimer's-related portions of this clinical staging continuum, they remain to be elucidated for cerebrovascular small vessel disease...
- High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trialPaul S Aisen
Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
JAMA 300:1774-83. 2008..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
- Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairmentMichael Grundman
Department of Neurosciences, University of California, San Diego, La Jolla 92093 0949, USA
J Mol Neurosci 20:241-8. 2003..We conclude that the relationship between hippocampal volume and risk of AD is likely tied to reduced memory performance and not associated with impairment in nonmemory cognitive domains...
- Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman
Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
Arch Neurol 61:59-66. 2004..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
- A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairmentLeon J Thal
University of California, San Diego, CA, USA
Neuropsychopharmacology 30:1204-15. 2005..In conjunction with the lack of effects observed in previous AD studies, the findings suggest that inhibition of COX-2 is not a useful therapeutic approach in AD...
- Effects of N-PEP-12 on memory among older adultsThomas H Crook
Psychologix, Inc, Fort Lauderdale, FL 33308, USA
Int Clin Psychopharmacol 20:97-100. 2005..N-PEP-12 may be an effective treatment for memory loss in healthy older adults...
- Barriers to drug discovery and development for Alzheimer diseaseHoward M Fillit
The Institute for the Study of Aging, Inc, New York, New York, USA
Alzheimer Dis Assoc Disord 16:S1-8. 2002..The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail...
- A phase I study of AIT-082 in healthy elderly volunteersMichael Grundman
Department of Neurosciences, University of California, San Diego, La Jolla 92037, USA
J Mol Neurosci 18:283-93. 2002..In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated...
- Clinical efficacy of piracetam in cognitive impairment: a meta-analysisTony Waegemans
Research and Development, UCB SA (Pharma Sector, Braine-l'Alleud, Belgium
Dement Geriatr Cogn Disord 13:217-24. 2002....
- Recommendations for best practices in the treatment of Alzheimer's disease in managed careHoward M Fillit
Alzheimer s Drug Discovery Foundation and Institute for the Study of Aging New York, New York 10019, USA
Am J Geriatr Pharmacother 4:S9-S24; quiz S25-S28. 2006..However, these clinical guidelines have not been updated in the past few years...